Imperial College London researchers propose a systemic, whole-body model of Alzheimer's disease. Read what this early hypothesis means for cognitive health.
On September 3, 2026, researchers at Imperial College London published a Communications Medicine Comment proposing a systemic model of Alzheimer's disease. The authors argue that the condition involves a body-wide biological failure that surfaces in the brain first.
The conventional research model has concentrated primarily on the brain. Within this framework, scientists focus heavily on two major proteins. These proteins are beta-amyloid and tau. Beta-amyloid forms plaques between brain cells, while tau forms tangles inside them.
The Imperial College London researchers suggest this brain-first framework misses the full complexity of the disease. They are calling for a broader model of Alzheimer's disease. This new approach examines interactions among the brain, the rest of the body and wider biological systems. The proposed model is systemic and multifactorial.
In this proposed framework, many bodily processes interact with neurodegeneration. These include cardiovascular health, diabetes and inflammation. Endocrine function, metabolism and genetic susceptibility are also involved. The model suggests treating cellular maintenance and brain health together rather than as separate issues.
The authors point to a common biological thread involving lysosomes and mitochondria. Lysosomes help cells clear waste safely. Mitochondria help produce energy for the body. Professor Payam Barnaghi is the corresponding author of the paper. He noted that Alzheimer's may originate as a body-wide failure of cellular clearance and energy production.
The researchers suggest that long-lived neurons may be particularly vulnerable. These neurons accumulate the effects of cellular dysfunction over many years.
The Imperial article points to an earlier analysis of UK Biobank hospital records. This analysis found that depressive episodes, osteoporosis and type 1 diabetes appeared up to 20 years before an Alzheimer's diagnosis. The authors also report on earlier research involving 1.75 million people. These individuals were registered with Scottish general practices in 2007.
That Scottish research found that multiple long-term conditions began 10 to 15 years earlier in the most deprived areas. This was measured against populations in the most affluent areas. This systemic proposal aligns with a wider trend in Alzheimer's research. Scientists are increasingly moving toward models that include vascular, metabolic, immune and protein-related processes together.
Recent systems-biology work also examines how genetic risk converges across molecular networks. These networks involve immune cells and lipid metabolism rather than operating through a single isolated pathway. Another adjacent research direction is the exposome approach. This approach studies how cumulative environmental exposures interact with ageing, genetics and biological responses.
These frameworks reflect a move away from single-cause explanations. Research into peripheral-central inflammatory crosstalk proposes another connected mechanism. This research suggests that chronic low-grade inflammation outside the brain may interact with the neurovascular unit. This interaction could influence brain immune processes over time. The Imperial paper notes that this remains an area of active investigation rather than a settled explanation of Alzheimer's disease.
For older adults, this theoretical shift reinforces the value of comprehensive health management. The immediate message is continuity rather than a dramatic change in medical advice. The Imperial proposal does not provide a new prevention protocol or treatment recommendation. The practical priority remains steady, evidence-based care.
Current guidance from the WHO applies to adults without dementia. This includes people with normal cognition or mild cognitive impairment. The guidance addresses healthy behaviours and health conditions associated with dementia risk. It also supports tailored multidomain interventions for cognitive protection.
The WHO recommends physical activity for adults with normal cognition and those with mild cognitive impairment. It also recommends managing diabetes in people who have the condition. Managing hypertension is also recommended as part of reducing cognitive-decline risk. You should work with a clinician to monitor and manage blood pressure if you have hypertension.
Treating cardiovascular, metabolic, inflammatory and endocrine conditions remains a cornerstone of overall health. If you are concerned about memory changes, seek a clinical assessment rather than relying on online risk claims. The Imperial article does not establish a blood test or body-wide screening programme for routine use. You can review our cognitive health and protection articles for more details on clinical assessments.
The most important caveat is that Imperial's proposal is a hypothesis rather than a proven mechanism. The paper notes that the exact causal mechanisms of Alzheimer's disease remain unclear. An association between a medical condition and a later Alzheimer's diagnosis does not show that the condition caused the disease. The earlier UK Biobank analysis relied on inpatient data, which may not represent complete health histories.
The presence of bodily conditions before diagnosis could reflect several possibilities. These include shared risk factors, early disease effects or biological relationships that are not yet understood. The Imperial article does not establish which explanation is correct. The article also does not prove that treating metabolic or inflammatory conditions prevents Alzheimer's disease.
The systemic hypothesis should not be presented as evidence that a particular supplement or diet prevents dementia. The researchers are calling for long-term, multi-organ studies to test their model. A whole-body model should not be mistaken for the claim that the brain is unimportant. Alzheimer's disease involves profound brain changes, amyloid accumulation, neuronal loss and cognitive decline.
Amyloid remains central to currently authorised disease-modifying treatments. Approved anti-amyloid therapies are designed for selected people with early symptomatic Alzheimer's disease. These medicines slow decline rather than stop or reverse the disease. Lecanemab and donanemab target amyloid and have shown modest slowing of cognitive decline.
These treatments offer functional benefits in selected patients with early symptomatic disease. They alter measurable pathology, but they are not cures. The Imperial authors argue that this modest clinical benefit might align with a broader disease model. They suggest Alzheimer's involves more than amyloid alone.
The article stresses that this broader interpretation is debated rather than conclusive. For people diagnosed with early symptomatic Alzheimer's disease, treatment decisions remain matters for specialist assessment. The new Imperial argument may eventually broaden treatment research. It does not replace current diagnostic or treatment pathways.
The proposed approach is best understood as a long-term research direction. The researchers want to determine whether dysfunction in cellular clearance and energy production contributes causally to Alzheimer's disease. They are not claiming that Alzheimer's has been shown to begin outside the brain. They also do not claim that lysosomal dysfunction is the proven initiating mechanism.
Professor Barnaghi argues that the systemic model could change how researchers search for causes. This approach encourages scientists to study interactions among organs and cellular systems rather than isolated brain mechanisms. The paper also raises an equity argument regarding patient care. Managing cardiovascular, metabolic and inflammatory conditions through ordinary healthcare could reach more people.
This routine care might help populations who might never receive specialised disease-modifying therapies. The Imperial article notes that this equity argument was not tested in the Comment itself. This broader biological framework seeks to identify which body-wide processes are causal rather than merely associated. It aims to determine whether interventions outside the brain can alter Alzheimer's progression.
Maintaining your physical health remains the most practical response to these developing theories. By focusing on established medical care, you can support your body while science investigates these complex biological connections. Reading trusted brain health resources can help you stay informed as this research evolves over the coming years. You can also review practical habit-building tips in our lifestyle and brain resilience articles.
Evaluating whether new whole-body Alzheimer's theories change your daily routine requires careful attention to the difference between clinical guidance and early hypotheses. Confusion about what normal brain aging looks like can make adjusting your lifestyle stressful, but FitBrainLab translates these medical debates into practical steps for long-term cognitive health.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.
Build habits that support memory, focus and a curious, connected life.
Read the Blog
